Sientra Inc. (SIEN) Upgraded by Zacks Investment Research to Hold
Sientra Inc. (NASDAQ:SIEN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
Separately, William Blair restated a “market perform” rating on shares of Sientra in a research note on Wednesday, August 10th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/sientra-inc-sien-upgraded-by-zacks-investment-research-to-hold.html
Shares of Sientra (NASDAQ:SIEN) opened at 9.00 on Wednesday. Sientra has a 12-month low of $2.78 and a 12-month high of $10.45. The firm’s market cap is $163.21 million. The firm’s 50-day moving average price is $8.46 and its 200 day moving average price is $7.41.
Sientra (NASDAQ:SIEN) last announced its earnings results on Tuesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by $0.05. Sientra had a negative net margin of 297.09% and a negative return on equity of 36.16%. The business earned $6.20 million during the quarter, compared to analyst estimates of $4.80 million. On average, equities analysts expect that Sientra will post ($2.31) earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. First New York Securities LLC NY raised its stake in shares of Sientra by 411.4% in the second quarter. First New York Securities LLC NY now owns 15,343 shares of the company’s stock worth $101,000 after buying an additional 12,343 shares during the period. Paloma Partners Management Co acquired a new stake in shares of Sientra during the second quarter worth $198,000. Geode Capital Management LLC raised its stake in shares of Sientra by 67.5% in the first quarter. Geode Capital Management LLC now owns 71,919 shares of the company’s stock worth $491,000 after buying an additional 28,980 shares during the period. State Street Corp raised its stake in shares of Sientra by 23.9% in the first quarter. State Street Corp now owns 82,717 shares of the company’s stock worth $563,000 after buying an additional 15,954 shares during the period. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Sientra during the second quarter worth $3,310,000. Institutional investors own 68.85% of the company’s stock.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.